Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J.,...
Month: June 2025
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero...
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
Company expected to resume trading on the NYSE American on Tuesday, June 17, 2025OCALA, Fla., June 12, 2025 (GLOBE NEWSWIRE)...
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero...
Nectero Medical Secures Category III CPT Codes for Investigational Therapy to Treat Small- to Medium-Sized AAAs
Milestone paves the way for future reimbursement of the Nectero EAST® SystemTEMPE, Az., June 12, 2025 (GLOBE NEWSWIRE) -- Nectero...
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025...
DiagnaMed Appoints John Karagiannidis as President & CEO; Fabio Chianelli Transitions to Director Role Strengthening Strategic Partnership with QIMC to Accelerate Natural Hydrogen Development in Ontario
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("”DiagnaMed” or “DMED") (CSE: DMED) (OTCQB: DGNMF), a Canadian technology...
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025...
Rgenta Therapeutics Presents Preclinical Data from Lead Program, RGT-61159, a Potent and Selective Small Molecule Inhibitor of MYB RNA, Supporting its Application in the Treatment of Acute Myeloid Leukemia (AML)
Data are being presented at the 30th Annual Congress of the European Hematology Association 2025 (EHA2025)WOBURN, Mass., June 12, 2025...
DiagnaMed Appoints John Karagiannidis as President & CEO; Fabio Chianelli Transitions to Director Role Strengthening Strategic Partnership with QIMC to Accelerate Natural Hydrogen Development in Ontario
TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("”DiagnaMed” or “DMED") (CSE: DMED) (OTCQB: DGNMF), a Canadian technology...
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Werewolf Therapeutics to Participate in the BIO International Convention
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected...
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected...
Aayush Wellness Bridging Ancient Ayurvedic Wisdom with Modern Wellness offering Aayush Herbal Masala – A Natural Alternative
NEW DELHI, India, June 12, 2025 (GLOBE NEWSWIRE) -- Aayush Wellness Limited, a trailblazer in India's preventive healthcare sector, seamlessly...
Aayush Wellness Bridging Ancient Ayurvedic Wisdom with Modern Wellness offering Aayush Herbal Masala – A Natural Alternative
NEW DELHI, India, June 12, 2025 (GLOBE NEWSWIRE) -- Aayush Wellness Limited, a trailblazer in India's preventive healthcare sector, seamlessly...
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing...
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing...